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Objective: Biomaterials and textured surfaces in early pulsatile left ventricular assist
devices (HeartMate I; Thoratec Corporation, Pleasanton, Calif) may increase immu-
nologic risk through allosensitization. We hypothesized that axial-flow devices with-
out biologic membranes or textured surfaces (HeartMate II; Thoratec; and DeBakey;
MicroMed Cardiovascular, Inc, Houston, Tex) would cause less allosensitization than
devices with such membranes and surfaces.
Methods:HeartMate II and DeBakey (n5 24) and HeartMate I (n5 36) devices were
implanted from 1999 to 2006 in patients with severe heart failure cohort-matched for
age, etiology, and support duration. Serum samples reacting with more than 10% of
the HLA reference panel were considered positive for anti-HLA antibodies. Endo-
myocardial biopsy samples were collected after transplant.
Results: There were no significant cohort differences in age, etiology, sex, blood
transfusion, or support duration. Anti-HLA antibodies were not detected at implanta-
tion of either HeartMate II and DeBakey or HeartMate I devices; however, significant
increases in anti-HLA antibodies were present within 1 and 3 months of support with
HeartMate I but not HeartMate II and DeBakey devices. Overall, fewer patients with
HeartMate II and DeBakey devices demonstrated positive anti-HLA antibodies dur-
ing support (8% vs 28%, P 5 .02), and fewer episodes of acute rejection per patient
were seen within the first 9 posttransplant months(0.31 vs 0.69, P5 .052). Long-term
posttransplant survival was not different between groups.
Conclusion: Hemodynamic support with HeartMate II and DeBakey devices pro-
duced less allosensitization than did HeartMate I devices. Device selection may
improve clinical outcomes for high-risk patients.
L
eft ventricular assist devices (LVADs) have become an established surgical
therapy for patients with end-stage heart failure who require hemodynamic
support as a bridge to transplant or as destination therapy. Allosensitization,
the development of circulating class I and II HLA antibodies, has become increasingly
common in the LVAD population and is estimated in some studies to be as high as
66%.1 Mechanical circulatory support with a first-generation pulsatile LVAD has
been shown to initiate a vigorous localized host immunologic response that may, in
conjunction with traditionally associated risk factors such as blood transfusions, pre-
vious operations, and pregnancy, be responsible for allosensitization in these patients.
The clinical consequences of allosensitization are not insignificant and negatively
affect rates of allograft rejection, transplant vasculopathy, and overall survival.2-6
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TXAbbreviations and Acronyms
HMI 5 HeartMate I
HMII-DB 5 HeartMate II or DeBakey
IL-2 5 interleukin 2
IL-6 5 interleukin 6
IVIG 5 intravenous immunoglobulin
LVAD 5 left ventricular assist device
OHT 5 orthotopic heart transplant
PRA 5 panel-reactive antibody
Newer generation axial-flow devices achieve blood flow
with a rotary impeller, lack biologic chamber valves, and pos-
sess a substantially smaller inner surface than do pulsatile
LVADs. It has been hypothesized that the lower surface
area and absence of biologic membranes in axial-flow de-
vices influences immunologic response relative to pulsatile
LVADs, and preliminary studies have reported low rates of
sensitization associated with axial-flow devices.7 To date,
no study has systematically compared the rate of allosensiti-
zation between the two device types. Accordingly, the objec-
tives of this study were as follows: (1) to determine the extent
to which device type influences allosensitization and (2) to
describe the impact of this immunologic response on allo-
graft rejection in orthotopic heart transplant (OHT) recipi-
ents. The effects of the device type on the host immune
system could have potentially important clinical conse-
quences when considering LVAD implantation as a bridge
to transplant in patients at high risk for development of
sensitization.
Methods
Study Design
Between June 1999 and April 2006 at Columbia University Medical
Center, 36 pulsatile HeartMate I (HMI group) LVADs (HeartMate I
VE, n 5 11, HeartMate I XVE, n 5 25; Thoratec Corporation,
Pleasanton, Calif) and 24 axial-flow HeartMate II or DeBakey
(HMII-DB group) LVADs (HeartMate II, n5 16; Thoratec; DeBa-
key, n 5 8; MicroMed Cardiovascular Inc, Houston, Tex) were
implanted in patients with severe heart failure. All patients met
accepted criteria for implantation. Pretransplant and posttransplant
clinical data were prospectively collected and retrospectively
analyzed for the purposes of this study. Patients who died while
on the waiting list were included in this analysis. This study was ap-
proved by the institutional review board, and all procedures were in
accordance with institutional guidelines and policies.
HLATyping and Crossmatch
Standard microcytoxicity techniques were used to determine HLA-
A and HLA-B serotypes, whereas serologic analysis was performed
to determine HLA-DR types. A donor-specific lymphocytic direct
crossmatch was performed before OHT for all patients with
a panel-reactive antibody (PRA) value greater than 20% and retro-
spectively (after OHT) for all patients.The Journal of ThorDetection of Anti-HLA Antibodies and Determination
of Anti-HLA Antibody Specificity
Lymphocytotoxic antibodies were detected by screening serum sam-
ples againstT andB lymphocytes collected from70persons represent-
ing allHLAclass I and II antigens in theNorthAmericanpopulation to
determine a PRAvalue. IgG antibodies against HLA class I or class II
molecules reacting with more than 10% of the HLA reference panel,
for a PRA value greater than 10%, were considered positive, as previ-
ously described.8 Testing was performed on all patients, beginning at
the time of LVAD implantation, every 2 weeks until OHT and at the
time of each posttransplant endomyocardial biopsy.
Immunosuppressive Regimen
The posttransplant immunosuppressive regimen consisted of combi-
nation therapy with cyclosporine, methylprednisolone, and myco-
phenolate mofetil, as previously described.1
Patients in whom an elevated PRA (greater than 10%) was
detected after listing for transplant were subsequently treated with
immunotherapy in 1- to 3-month course treatments with intravenous
cyclophosphamide (1.0 g/m2) and pooled human intravenous immu-
noglobulin (IVIG, 2 g/kg in four divided doses). This protocol from
our institution has been described previously.1 Briefly, weekly test-
ing for anti-HLA antibodies was performed, and two treatments of
plasmapheresis were given if a significant drop in antibody levels
was not seen after several treatments. This was followed by intrave-
nous cyclophosphamide given in monthly doses. This treatment was
repeated as necessary, and patients with a negative direct crossmatch
could proceed to OHT during this time period. Transplant recipients
who were sensitized at any point during device support received
monthly cyclophosphamide for 4 to 6 months after OHT.
Acute Rejection
Endomyocardial biopsies were performed after OHT as standard
protocol weekly for the first 4 weeks, every second week for 2
months, every month for the next three biopsies, and then every 2
months for the first year. An International Society for Heart and
Lung Transplantation histologic grade of 2 or higher was considered
to represent allograft rejection for the purposes of this study. Treat-
ment for acute rejection consisted of a 3-day steroid pulse. Antithy-
mocyte globulin or murine antibody was used in patients with
hemodynamically significant rejection.
Interleukin 6
Interleukin 6 (IL-6), an important regulatory immunocytokine in-
volved in B-cell differentiation and interleukin 2 (IL-2) expansion,
was measured at the end of LVAD support at the time of OHT in
serum samples from 6 HMII-DB and 11 HMI patients to determine
whether levels varied according to device type or correlated with the
incidence of rejection after OHT. A commercially available en-
zyme-linked immunosorbent assay (Human IL-6; Bender MedSys-
tems, Vienna, Austria) was used to determine absorption curves for
standards and samples at 450 nm. A linear regression was performed
to determine values according to manufacturer specifications.
Statistics
Continuous variables are expressed as mean 6 SD and were com-
pared with independent 2-tailed t tests. Categorical variables were
compared with c2 and Mann–Whitney tests, and when necessaryacic and Cardiovascular Surgery c Volume 135, Number 6 1373
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HMI HMII-DB P value
No. 36 24
Age (y, mean 6 SD) 52.0 6 12.5 53.1 6 12.0 .723
Male (No.) 30 (83%) 20 (83%) ..999
LVAD implanted
HeartMate I (No.) 36 (100%) 0 (0%) ,.001
HeartMate II (No.) 0 (0%) 16 (67%) ,.001
DeBakey (No.) 0 (0%) 8 (33%) ,.001
Etiology of CHF (No.)
Ischemic 18 (50%) 10 (42%) 1.000
Nonischemic 18 (50%) 14 (58%) 1.000
Pre-LVAD ejection fraction (%, mean 6 SD) 17.6% 6 4.5% 17.5% 6 4.2% .820
Duration of CHF (mo, mean 6 SD) 51.2 6 59.7 71.0 6 64.6 .209
Duration of LVAD support (d, mean 6 SD) 107.3 6 112.2 91.9 6 117.8 .610
Previous pregnancy (No.) 1 (2.8%) 2 (8.3%) .337
Bridge to transplant (No.) 36 (100%) 22 (92%) .081
Successful bridge to transplant (No.) 32 (89%) 13 (54%) ,.001
Awaiting transplant (No.) 0 (0%) 6 (25%) .014
Died during LVAD support (No.) 4 (11%) 5 (38.4%) .306
Died after transplant (No.) 7 (22%) 2 (15%) .242
Medications (No.)
b-Blocker 4 (11%) 8 (33%) ,.001
Diuretic 9 (25%) 12 (50%) .049
Angiotensin-converting enzyme inhibitor 3 (8%) 6 (25%) .079
Aspirin 8 (22%) 13 (54%) .001
Antibiotic 7 (19%) 6 (25%) .612
Steroid 3 (8%) 1 (4%) .530
Statin 1 (3%) 2 (8%) .337
Infections (No.)
Device 8 (22%) 1 (4%) .001
Wound 7 (19%) 0 (0%) ,.001
Cerebrovascular accident (No.) 3 (8%) 3 (13%) .601
Previous surgery (No.)
Cardiac 5 (14%) 0 (0%) .059
Other 5 (14%) 3 (13%) .878
Previous transplant (No.) 1 (3%) 1 (4%) .771
HMI, HeartMate I group; HMII-DB, HeartMate II and DeBakey group; LVAD, left ventricular assist device; CHF, congestive heart failure.with Fisher exact tests. Kaplan–Meier analysis was used to calculate
survival, and groups were compared with a 2-sided log-rank test at
the P5 .05 significance level. Actuarial survivals at 6 months and at
1 and 2 years after OHT were calculated by constructing life tables.
All data were analyzed with the software package SPSS 11.5 (SPSS
Inc, Chicago, Ill).
Results
Demographics
Table 1 summarizes demographic and clinical characteristics
of HMI and HMII-DB groups. Age, sex, etiology of conges-
tive heart failure, pre-LVAD ejection fraction, and duration
of heart failure were similar between HMI and HMII-DB
groups. Patients in the HMI cohort were supported for
107.3 6 112.2 days, versus 91.9 6 117.8 days in the
HMII-DB cohort (P 5 .610). All HMI devices were1374 The Journal of Thoracic and Cardiovascular Surgery c Juimplanted as a bridge to transplant; all but two HMII-DB
deviceswere implanted as bridge to transplant. Previous preg-
nancy was uncommon in both groups. A slightly higher per-
centage of HMII-DB patients than HMI patients died while
awaiting OHT (P 5 .306); a significantly higher percentage
of HMII-DB patients were awaiting OHT at the time of anal-
ysis (P 5 .014), contributing to the lower rate of successful
bridging to transplant in the HMII-DB group (P , .001).
The medical regimens of patients during LVAD support
were similar except for a higher proportion of HMII-DB
patients treated with b-blocker therapy (P , .001), aspirin
(P 5 .001), and diuretics (P 5 .049). A higher rate of
wound and device infections was observed in the HMI group
than in the HMII-DB group (P 5 .001). Rates of previous
surgery and previous transplant were comparable among
both groups.ne 2008
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The transfusion histories for all patients during LVAD sup-
port at our institution are listed in Table E1. Most transfu-
sions in both HMI and HMII-DB groups were leukofiltered
red blood cells, and total rates of transfusions per patient
were similar between groups (P 5 .953).
Anti-HLA Antibodies and Immunotherapy
A total of 10 HMI (27.7%) and 2 HMII-DB (8.3%) patients
developed detectable anti-HLA antibodies reacting with
greater than 10% of the HLA reference panel during the
course of LVAD support, (P 5 .025; Figure 1, A). A higher
percentage of patients in the HMI group than in the HMII-DB
group were found to be sensitized on examination within 1
and 3 months after device implantation (P , .001, P 5
.021, respectively; Figure 2, A), and a trend toward increased
mean peak PRA levels was observed in the HMI group at 3
months (P5 .09; Figure 2, B). In the HMI group, 3 of 10 sen-
sitized patients (30%) had IgG antibodies to class I mole-
cules, 5 (50%) had IgG antibodies to class II molecules,
and 2 (20%) had antibodies to both class I and class II mol-
ecules. In contrast, both the sensitized patients in the HMII-
DB group had IgG antibodies against both class I and class
II molecules. Immunotherapy with IVIG and cyclophospha-
mide was instituted in both HMI (IVIG n 5 10, cyclophos-
phamide n 5 5) and HMII-DB (IVIG n 5 2,
cyclophosphamide n 5 2) patients with sensitization (P 5
.001), resulting in only 20% of HMI and 7.7% of HMII-
DB patients with elevated antibodies at OHT (Figure 1, B).
Sensitized patients from the HMI and HMII-DB groups
had average durations of LVAD support of 128.0 6 91.2
and 79.0 6 59.4 days, respectively (P 5 .437). Seven of
10 sensitized HMI patients and 1 of 2 sensitized HMII-DB
patients were male, and 1 HMII-DB patient had a previous
pregnancy. Rates of infection and previous surgery wereThe Journal of Thoracomparable between sensitized groups, and the HMI group
averaged 34.7 1 23.74 total transfusions vs 40.5 1 20.7
the for HMII-DB group (P5 .753). There was no significant
difference in waiting times between sensitized and nonsensi-
tized patients in this study (229.5 6 144.9 days vs 168.0 6
173.2 days, respectively, P 5 .418).
Donor and Recipient Characteristics
The clinical characteristics of 32 HMI and 13 HMII-DB pa-
tients successfully bridged to transplant are listed in Table 2.
The age, duration of heart failure, duration of support, trans-
fusion rate, cytomegalovirus status, waiting time, and donor
characteristics were comparable between HMI and HMII-DB
groups. Almost three quarters of all transplant recipients were
listed as United Network for Organ Sharing status 1A.
Acute Rejection
Patient follow-up after OHT was 9 months for both HMI and
HMII-DB groups. Acute rejection within the first 9 months
after OHT was documented in 16 patients in the HMI group
(50%, 0.69 episodes/patient) and only 3 in the HMII-DB
group (23%, 0.31 episodes/patient, P 5 .052; Figure 2, C).
Sensitization, or the development of anti-HLA antibodies
during LVAD support, may translate to a higher rate of acute
rejection within the first 9 months, as evidenced by the fact
that 5 HMI patients (50%) and 0 HMII-DB patients (0%)
who were sensitized had rejection occur (P 5 .455).
Actuarial Survival
Kaplan–Meier survival curves after OHT with life tables for
sensitized and nonsensitized HMI and HMII-DB patients
were constructed for 6-month and 1-year time points. Sensi-
tization did not statistically affect short-term survival after
OHT in either LVAD group at 6 months (HMI 88.9% vsTXFigure 1. A, Overall percentage of patients sensitized at any time during left ventricular assist device support by
device type. Asterisk indicates P 5 .025 versus HeartMate I. HMI, HeartMate I; HMII-DB, HeartMate II or DeBakey.
B, Percentage of sensitized patients before transplant (P 5 .590). HMI, HeartMate I; HMII-DB, HeartMate II or
DeBakey.cic and Cardiovascular Surgery c Volume 135, Number 6 1375
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device type. Asterisk indicates P< .001 versus HeartMate I at 1 month; dagger indicates P5 .021 versus HeartMate I
at 3 months. HMI, HeartMate I; HMII-DB, HeartMate II or DeBakey. B, Mean peak panel reactive antibody (PRA)
levels during first 3 months of left ventricular assist device (LVAD) support and before transplant by device type
(HeartMate II or DeBakey vs HeartMate I, P5 .09 at 3 months). HMI, HeartMate I; HMII-DB, HeartMate II or DeBakey.
C, Acute rejection within first 9 months after transplant was increased after HeartMate I (HMI) support versus
HeartMate II or DeBakey (HMII-DB) support when examining all patients undergoing transplant. Asterisk indicates
P 5 .052 versus HeartMate I.HMII-DB 100%) or at 1 year (HMI 77.8% vs HMII-DB
100%, log-rank P 5 .78).
Interleukin 6
IL-6, measured after device support at the time of OHT,
was significantly lower in the HMII-DB group than in the
HMI group, despite equivalence in duration of support,
age, etiology of heart failure, previous operation rate, previ-
ous pregnancy rate, and transfusion rate (6.44 6 2.45 vs
22.02 6 5.39 ng/mL, respectively, P , .001). In the group
of patients with IL-6 levels measured, none of the HMII-
DB patients and only 1 HMI patient had a clinically rele-
vant infection.1376 The Journal of Thoracic and Cardiovascular Surgery c JuDiscussion
The population of patients with congestive heart failure who
receive LVAD support as a bridge to transplant has in-
creased, as have hazards associated with device exposure,
namely allosensitization. The ability to characterize and
modulate factors affecting long-term outcomes after mechan-
ical support and OHT is of paramount importance because of
the scarcity of donor organs for transplant. In this study, the
rate of allosensitization in patients after mechanical support
with either HMII-DB or HMI devices was studied, and the
primary clinical outcomes of acute rejection and survival
were compared. The primary findings were as follows: (1)
patients with HMII-DB devices demonstrated lower ratesne 2008
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HMI HMII-DB P value
Recipient
No. 32 13
Age (y, mean 6 SD) 51.9 6 13.0 51.2 6 12.7 .865
Male (No.) 28 (88%) 11 (85%) .799
LVAD implanted (No.)
HeartMate I 32 (100%) 0 (0%) ..999
HeartMate II 0 (0%) 7 (54%) ..999
DeBakey 0 (0%) 6 (46%) ..999
Etiology (No.)
Ischemic 16 (50%) 7 (54%) .817
Nonischemic 16 (50%) 6 (46%) .817
Duration of congestive heart failure (mo, mean 6 SD) 48.1 6 56.3 60.7 6 47.8 .245
Duration of LVAD support (d, mean 6 SD) 117.3 6 114.9 132.2 6 145.4 .745
Anti-HLA antibodies .10% (sensitized, No.) 9 (28.1%) 1 (7.7%) .002
Transfusions during LVAD support 0.123
Total 1034 562
Per patient (mean) 32.3 43.2
United Network for Organ Sharing status (No.)
1A 20 (63%) 9 (69%) .672
1B 12 (37%) 4 (31%) .732
Positive cytomegalovirus status after transplant (No.) 21 (66%) 11 (85%) .281
Waiting time (d, mean 6 SD) 187.5 6 300.2 185.0 6 145.9 .971
Donor
Age (y, mean 6 SD) 31.4 6 11.2 31.6 6 10.4 .949
Ischemic time (min, mean 6 SD) 181.6 6 49.0 208.9 6 45.5 .179
HLA locus complete mismatch (No.)
HLA-A 22 (69%) 8 (62%) .797
HLA-B 26 (81%) 10 (77%) .931
HLA-DR 18 (56%) 8 (62%) .611
Positive direct crossmatch (No.) 1 (3%) 0 (0%) .524
HMI, HeartMate I group; HMII-DB, HeartMate II or DeBakey group; LVAD, left ventricular assist device.TXof allosensitization through the duration of support, and (2)
sensitization did not affect short-term survival in either the
HMII-DB or the HMI group. Clinical follow-up suggested
a trend toward lower rejection rates in the HMII-DB group,
particularly in sensitized patients. These findings in the two
device groups were independent of duration of support, num-
ber of previous operations and blood transfusions, and age.
Patients traditionally at risk for allosensitization include
those with increased antigenic exposure, such as patients re-
ceiving multiple blood products, those undergoing multiple
transplants, those with other previous operations, and those
with a history of pregnancy.9-12 LVAD support with the
HMI device has increased the percentage of transplant recip-
ients with anti-HLA antibodies to class I and class II immu-
noglobulins anywhere from 17% to 66% in some studies.1,13
Host interactions with device biomaterials, specifically the
textured chamber surface, polyurethane diaphragm, and pol-
ytetrafluoroethylene components found in the HMI LVAD,
have been proposed as one mechanism responsible for an in-
creased immunologic and inflammatory response seen afterThe Journal of ThorLVAD support. A number of important immunologic obser-
vations have been made in support of this hypothesis:
aberrant T-cell activation on the LVAD surface,8 defective
T-cell proliferation,14 and polyclonal B-cell hyperreactivity
with CD40 ligand interactions.14-16 The pseudointima
formed on the textured surface of the Thoratec HMI device
contains an abundance of T cells, macrophages, and mono-
cytes and reflects the constant interaction of blood with the
device. The presence of both LVAD material and IL-2 is
required for cultured T cells from this membrane to survive,
indicative of a heightened cellular response to the LVAD sur-
face.17 High levels of CD95, a T-cell activation marker asso-
ciated with apoptosis, are found in circulating CD4 and CD8
cells after LVAD implantation, reflecting systemic activa-
tion. The cytokine profile associated with pulsatile LVADs
has also been examined, showing selective loss of T cells
with expression of TH1-type cytokines. IL-6, a critical cyto-
kine involved in B-cell differentiation, IL-2 expansion, C5a–
mediated complement activation, and intrinsic coagulation
activation, may contribute to both proimmunologic andacic and Cardiovascular Surgery c Volume 135, Number 6 1377
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tients with LVAD support have been shown to possess higher
levels of circulating anti-HLA antibodies and antiphospholi-
pid antibodies, consistent with systemic polyclonal B-cell
activation.
Axial-flow devices have been hypothesized to lower the
immunologic and inflammatory response seen after pro-
longed support as a result of lower overall textured surface
area (textured surfaces are found only along the inflow can-
nula of the HeartMate II device) and absence of biologic
chamber valves. As reported in a previous case series of 14
patients,7 support with the DeBakey device resulted in no pa-
tients with detectable anti-HLA antibodies as measured by
complement dependent cytotoxicity. This study’s data sup-
port those findings in a larger number of patients; axial-
flow devices were associated with a significantly lower rate
of allosensitization than were pulsatile devices when com-
pared in a standardized clinical regimen. Our rate of sensiti-
zation with pulsatile devices of 27.7% was similar to most
previously reported rates and lower than the previously
reported rate at our institution (66%).1 Conflicting rates of
sensitization exist, however, for axial-flow devices; one se-
ries of 19 consecutive patients receiving the DeBakey device
reported a sensitization rate of 10.5%,12 whereas Grinda and
colleagues7 found that no patients of 14 with the same device
became sensitized. The inability to account for differences in
transfusion rates and the small sample size, respectively, limit
conclusions from these studies.
The comorbidities of both cohorts highlight the recent
trend toward LVAD support for sicker patients who have
had more previous operations, more blood transfusions,
and longer duration of heart failure. The two LVAD cohorts
had equal rates of previous operations, amounts of blood
transfusions, previous transplants, duration of heart failure,
etiology of heart failure, and duration of LVAD support. Spe-
cific risk factors for allosensitization, such as previous preg-
nancy and platelet transfusions, were comparable between
HMI and HMII-DB groups. The high rate of anti-HLA anti-
bodies in the HMI group suggests that an intrinsic component
of pulsatile devices accounted for immunologic sensitization.
Patients in the HMI group produced ant-HLA antibodies
earlier in the course of LVAD support than did those in the
HMII-DB group, and they required more immunotherapy.
The success of immunotherapy, as documented in other
series,1 resulted in fewer patients in our study undergoing
OHT with elevated anti-HLA antibodies. As a result of our
common use of immunotherapy,1 sensitization did not in-
crease the waiting time for transplant in our study. Finally,
the higher rate of sensitization in the HMI group did not affect
the rate of successful bridge to transplant.
Allosensitization may have important clinical conse-
quences for the short and long-term outcomes of cardiac
transplant recipients. In a large cohort study, 3-year survival
after OHT was significantly lower for patients with a PRA1378 The Journal of Thoracic and Cardiovascular Surgery c Junlevel greater than 11%.6 The degree of sensitization has
also been shown to be an independent risk factor for de-
creased survival,20 and higher rates of acute rejection and
transplant vasculopathy have been associated with sensitiza-
tion.2-6 These findings have been confirmed for sensitization
occurring in the setting of LVAD support as well.15 Other
complications, such as infections, thromboembolism, and in-
creased waiting times, are due in part to logistic constraints
imposed by the necessity of crossmatching before transplant
and a smaller donor pool. More recent data suggest that
outcomes of sensitized patients after immunotherapy do not
differ from those of non-sensitized patients.1,21 Despite the
small sample sizes, a lower overall rate and fewer total epi-
sodes of rejection were seen in HMII-DB patients in this
study; of the HMII-DB patients with sensitization, none
had rejection, whereas a higher proportion of sensitized
HMI patients eventually had acute rejection. This finding is
consistent with the hypothesis that systemic immune re-
sponse is heightened and more vigorous in patients supported
with pulsatile devices, possibly as a result of sustained and
persistent stimulus of B- and T-cell activation by device bio-
materials. In support of this theory, elevated levels of IL-6,
a regulatory cytokine critical in IL-2 induction, B-cell expan-
sion, and the acute-phase reaction, were found in the HMI
group and could not be accounted for by other causes of
IL-6 elevation, such as bacteremia, autoimmune diseases,
proliferative diseases, or neoplastic conditions. IL-6 may
also be involved in acute rejection, with elevated levels found
before acute rejection in kidney transplant recipients.19,22 It is
also notable that infection may be temporally related to im-
munologic sensitization, because 7 of 8 HMI patients with
an infection showed sensitization during the same observa-
tion period; the possibility of synergistic mechanisms has
yet to be studied. Finally, survival was not affected by sensi-
tization in either the HMI or the HMII-DB group, because
immunotherapy was effective in lowering the percentage of
patients with elevated antibodies before OHT. Improved
immunosupression and surveillance may also contribute to
better overall post-LVAD and posttransplant care.
A number of limitations in this study must be noted. The
HMI group had a slightly higher rate of wound and device in-
fection, and although this did not result in sustained bacter-
emia, it may have influenced overall outcomes after OHT.
The small sample sizes and disparity in number of HMI
and HMII-DB patients undergoing OHT require our findings
to be confirmed in the future, as axial-flow device use be-
comes more prevalent. A distinct learning curve exists with
LVAD technology, and this data set included patients with
LVADs implanted more than 5 years ago. Newer and
improved surgical techniques may have affected the overall
care and medical regimen of the patients, thus affecting out-
comes and sensitization. Finally, although patients were
matched for risk factors, the study population was not ran-
domized, and the possibility of selection bias exists.e 2008
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ing evidence that axial-flow devices are associated with
lower rates of allosensitization than are pulsatile devices in
a case-control setting. Patients in the HMII-DB group had
fewer anti-HLA antibodies later in the course of support,
and this resulted in fewer severe episodes of acute rejection.
The high number of multiple rejections and elevated cytokine
profile in the HMI group suggests sustained immunologic
activation by device biomaterial components, which may
contribute significantly to the development of sensitization.
Finally, immunotherapy is an effective treatment for allosen-
sitization during LVAD support when given before OHT. An
increased understanding of host interactions with LVAD bio-
materials may improve outcomes in the future, warranting
further study into specific immunologic mechanisms.
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TXTABLE E1. Transfusions during left ventricular assist device support
HMI HMII-DB P value
Total red blood cells 544 (15.11) 394 (16.42) .703
Washed 0 (0) 1 (0.04) .328
Irradiated 6 (0.17) 0 (0.0) .419
Leukofiltered 1 (0.03) 15 (0.63) .170
Leukofiltered and irradiated 492 (13.67) 278 (11.58) .958
Leukofiltered and tested for sickle cell 1 (0.03) 1 (0.04) .783
Leukofiltered, irradiated, and tested for sickle cell 44 (1.22) 46 (1.92) .329
Total fresh-frozen plasma, thawed 247 (6.86) 83 (3.46) .078
Total liquid plasma 172 (4.78) 99 (4.13) .794
Total platelets (pheresis) 123 (3.42) 63 (2.63) .550
Total factor VII 0 (0) 4 (0.17) .103
Total cryoprecipitate, thawed 111 (3.08) 115 (4.79) .200
Total cryoprecipitate, depleted 64 (1.78) 33 (1.38) .561
Total transfusions 1261 (35.0) 846 (35.3) .953
All values represent total units administered to group, with mean units per patient in parentheses. HMI, HeartMate I group;HMII-DB, HeartMate II or DeBakey
group.1379.e1 The Journal of Thoracic and Cardiovascular Surgery c June 2008
